Abstracts tagged "Antiphospholipid antibodies"

Abstract Number: 7 • 2017 ACR/ARHP Annual Meeting
Predictive Value for Thrombosis of Double or Triple Positivity in Secondary APS Depends on the Component Assays and the Type of Thrombosis
Michelle Petri¹, Daniel Goldman² and Laurence S Magder³, ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: The lupus anticoagulant (LAC) is individually the antiphospholipid antibody (aPL) most associated with thrombotic risk in both primary and secondary APS. Anticardiolipin (aCL) and…
Abstract Number: 9 • 2017 ACR/ARHP Annual Meeting
Renal Protective Effect of Antiplatelet Therapy in Antiphospholipid Antibody-Positive Lupus Nephritis Patients without the Antiphospholipid Syndrome
Hironari Hanaoka¹, Tomofumi Kiyokawa¹, Harunobu Iida¹, Yukiko Takakuwa¹, Takahiro Okazaki², Hidehiro Yamada³, Shoichi Ozaki⁴ and Kimito Kawahata¹, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ³Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan, ⁴Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Lupus nephritis (LN) class III or IV is associated with a poor prognosis for both patient and renal survival. Since antiphospholipid syndrome (APS) is…
Abstract Number: 115 • 2017 Pediatric Rheumatology Symposium
Anti-Phospholipid Antibodies in Children with Down Syndrome
Buthaina Al-Adba¹, Haitham El Bashir², Khalid ZahrAldin³, Ronald Thomas^4,5, Mohammad Al-Khalifa⁶, Asmaa Al-Marwani⁶, Dekra Al-Faridi⁶, Muhamad Al Dabbagh⁷ and Basil Fathalla³, ¹Pediatrics - Rheumatology, Hamad Medical Corporation, Doha, Qatar, ²Developmental Pediatrics & Children’s Rehabilitation - Department of Pediatrics, Hamad Medical Corporation, Doha, Qatar, ³Pediatrics, Hamad Medical Corporation, Doha, Qatar, ⁴Department of Research and Biostatistics, Children's Hospital of Michigan, Detroit, MI, ⁵Children's Research Center, Wayne State University, Detroit, MI, ⁶Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar, ⁷Department of Pediatrics, Hamad Medical Corporation, Doha, Qatar
Background/Purpose: The prevalence of anti-phospholipid antibodies (APL) in children with Down syndrome (DS) is unknown. Furthermore, it is unknown if an intermittent or persistent presence…
Abstract Number: 2093 • 2016 ACR/ARHP Annual Meeting
Association of Conventional Risk Factors and Antiphospholipid Antibodies to Thrombosis in Patients with Autoimmune Diseases: Lessons Learned from a Year-Long Systematic Assessment
Polona Žigon¹, Anuška Podovšovnik², Ales Ambrozic³, Matija Tomsic¹, Alojzija Hocevar¹, Natasa Gaspersic³, Ziga Rotar¹, Sonja Praprotnik⁴, Snezna Sodin Semrl^1,5 and Saša Čučnik^1,6, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Divison of Internal Medicine, General Hospital Izola, Izola, Slovenia, ³Department of Rheumatology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia, ⁴Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia, ⁵Faculty of Mathematics, Natural Science and Information Technology, University of Primorska, Koper, Slovenia, ⁶Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia
Background/Purpose: Patients with autoimmune disorders are at risk for thrombotic events and antiphospholipid antibodies (aPL) are one of known markers of increased thrombotic risk. The…
Abstract Number: 2094 • 2016 ACR/ARHP Annual Meeting
Complement Activation in Antiphospholipid Syndrome Due to the Multi-Activated Pathways of the Complement System
Hiroyuki Nakamura¹, Kenji Oku², Ryo Hisada², Kazumasa Ohmura², Masaru Kato², Toshiyuki Bohgaki², Olga Amengual², Tetsuya Horita², Shinsuke Yasuda² and Tatsuya Atsumi², ¹Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Complement activation is proposed as one of the major thrombophilic mechanisms in antiphospholipid syndrome (APS). Among three complement pathways (classical, alternative and lectin), activation…
Abstract Number: 2097 • 2016 ACR/ARHP Annual Meeting
Cardiolipin-Producing Candidate Commensals in the Gut Microbiome of Antiphospholipid Syndrome Patients
Cassyanne L. Aguiar^1,2, William Ruff³, Andrew Goodman⁴, Doruk Erkan⁵ and Martin Kriegel^3,6, ¹Hospital for Special Surgery- NewYork-Presbyterian / Weill Cornell Medicine, New York, NY, ²Pediatric Rheumatology, Cohen Children's Medical Center / Hofstra Northwell School of Medicine, Lake Success, NY, ³Immunobiology, Yale School of Medicine, New Haven, CT, ⁴Microbial Pathogenesis, Yale School of Medicine, New Haven, CT, ⁵Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ⁶Medicine, Section of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: Pathogen-associated transient antiphospholipid antibodies suggest a microbial trigger for antiphospholipid syndrome (APS). We hypothesized that the gut microbiota could represent a chronic stimulus in…
Abstract Number: 2099 • 2016 ACR/ARHP Annual Meeting
Micrornas As Potential Modulators of Atherothrombosis in Antiphospholipid Syndrome
Patricia Ruiz-Limon¹, Maria Ángeles Aguirre Zamorano², Nuria Barbarroja², Yolanda Jiménez-Gómez², IVÁN ARIAS DE LA ROSA², Eduardo Collantes-Estévez², Pedro Segui², Francisco Velasco³, Rocio Gonzalez-Conejero⁴, Raul Teruel⁴, Constantino Martinez⁴, Maria Jose Cuadrado⁵, Carlos Perez-Sanchez² and Chary Lopez-Pedrera², ¹Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Hematology, IMIBIC-Reina Sofia Hospital, Hematology Unit, Cordoba, Spain, ⁴Regional Centre for Blood Donation, University of Murcia, Murcia, Spain, ⁵St Thomas Hospital, Lupus Research Unit, London, United Kingdom
Background/Purpose: 1) To identify and characterize microRNAs linked to thrombosis and atherosclerosis development in APS; 2) To assess the effects of antiphospholipid antibodies in that…
Abstract Number: 2456 • 2016 ACR/ARHP Annual Meeting
Risk Factors for Adverse Pregnancy Outcome in Antiphospholipid Antibodies Carriers: Results from a Multicenter Italian Cohort over 20 Years of Experience
Maria Grazia Lazzaroni¹, Laura Andreoli¹, Cecilia B. Chighizola², Teresa Del Ross³, Maria Gerosa⁴, Anna Kuzenko³, Maria Gabriella Raimondo⁴, Andrea Lojacono⁵, Sonia Zatti⁵, Francesca Ramazzotto⁵, Laura Trespidi⁶, Pier Luigi Meroni⁷, Vittorio Pengo³, Amelia Ruffatti³ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Department of Clinical Sciences and Community Health, University of Milan, IRCCS Istituto Auxologico Italiano, Milano, Italy, ³Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, ⁴University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁵Obstetrics and Gynecology, Spedali Civili and University of Brescia, Brescia, Italy, ⁶L.Mangiagalli Obstetric Clinic, IRCSS Cà Granda, Ospedale Maggiore of Milano, Milano, Italy, ⁷Hospital G.Pini, University of Milano, IRCSS Instute Auxologico Italiano, Milano, Italy
Risk Factors for Adverse Pregnancy Outcome in Antiphospholipid Antibodies Carriers: Results From a Multicenter Italian Cohort Over 20 Years Of Experience Background/Purpose: Antiphospholipid antibodies (aPL)…
Abstract Number: 2457 • 2016 ACR/ARHP Annual Meeting
Role of Hydroxychloroquine in Improving Pregnancy Outcomes in Women with Antiphospholipid Antibodies without Other Underlying Connective Tissue Disease
Savino Sciascia¹, Simone Baldovino², Dario Roccatello² and Maria Jose Cuadrado³, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, ³St Thomas Hospital, Lupus Research Unit, London, United Kingdom
Background/Purpose: Heparins and/or low-dose aspirin represent the treatment of choice for the management of pregnant women with antiphospholipid antibodies (aPL). However, despite these treatments, maternal, fetal, and…
Abstract Number: 2798 • 2016 ACR/ARHP Annual Meeting
Multi-Center Validation of Platelet Bound C4d, a Biomarker for Systemic Lupus Erythematosus
Richard Furie¹, Anca D. Askanase², Kenneth Kalunian³, Elena Massarotti⁴, Rosalind Ramsey-Goldman⁵, Daniel J Wallace⁶, Stuart L. Silverman⁷, Smitha Reddy⁸, Puja Chitkara⁹, Chaim Putterman¹⁰, Christopher Collins¹¹, Jill P. Buyon¹², Cristina Arriens¹³, Tyler O'Malley¹⁴, Roberta Alexander¹⁵, Derren Barken¹⁶, John Conklin¹⁷, Susan Manzi¹⁸, Joseph Ahearn¹⁹, Arthur Weinstein²⁰ and Thierry Dervieux¹⁴, ¹North Shore University Hospital, Great Neck, NY, ²Medicine, Rheumatology, Columbia University Medical Center, New York, NY, ³Center for Innovative Therapy, UCSD School of Medicine, La Jolla, CA, ⁴Rheumatology, Immunology, & Allergy, Harvard Medical School, Brigham & Women's Hosp, Boston, MA, ⁵FSM, Northwestern University, Chicago, IL, ⁶Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Cedars, Beverly Hills, CA, ⁸Arthritis Care and Research Center, Inc., Poway, CA, ⁹Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA, ¹⁰Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ¹¹MedStar Washington Hospital Center, Washington, DC, ¹²Medicine, New York University School of Medicine, New York, NY, ¹³Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Research and Development, Exagen Diagnostics, Vista, CA, ¹⁵Research & Development, Exagen Diagnostics, Vista, CA, ¹⁶Exagen Diagnostics, Vista, CA, ¹⁷1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ¹⁸Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, ¹⁹Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, PA, ²⁰Rheumatology Section, Washington Hospital Center, Washington, DC
Background/Purpose: Previous studies have established the value of measuring complement activation products (C4d) bound to platelets (PC4d) for the diagnosis and monitoring of Systemic Lupus…
Abstract Number: 920 • 2016 ACR/ARHP Annual Meeting
Autoantigen-Specific T Cell and Antibody Reactivity to a Human Gut Commensal in Antiphospholipid Syndrome
William Ruff¹, Carina Dehner², Alex Roth¹, Silvio M. Vieira¹, Cassyanne L. Aguiar^3,4, Andrew Goodman⁵, Doruk Erkan⁶ and Martin Kriegel¹, ¹Immunobiology, Yale School of Medicine, New Haven, CT, ²Immunobiology, Yale School of Medicine, new haven, CT, ³Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Cohen Children's Medical Center of New York/ Hofstra Northwell School of Medicine, Pediatric Rheumatology, New York, NY, ⁵Microbial Pathogenesis, Yale School of Medicine, New Haven, CT, ⁶Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY
Autoantigen-specific T Cell and Antibody Reactivity to a Human Gut Commensal in Antiphospholipid Syndrome William Ruff1, Carina Dehner1, Alex Roth1, Silvio M. Vieira1, Cassyanne L.…
Abstract Number: 2919 • 2016 ACR/ARHP Annual Meeting
Prevalence of Antiphospholipid Antibodies and Their Clinical Associations in Systemic Sclerosis: Data from a French Cohort
Angélique Lemaire^1,2, Vincent Sobanski^2,3,4,5, Jonathan Giovannelli⁶, Eric Hachulla^1,2,4,5, Sylvain Dubucquoi^4,7, Marc Lambert^1,2,4,5, Pierre-Yves Hatron^1,2,6 and David Launay^1,2,4,5, ¹CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, ²CHU Lille, Centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique), F-59000 Lille, France, Lille, France, ³CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, ⁴Univ. Lille, U995, Lille Inflammation Research International Center (LIRIC), F-59000 Lille, France, Lille, France, ⁵Inserm, U995, F-59000 Lille, France, Lille, France, ⁶Univ Lille, CHU Lille, F-59000 Lille, France, Lille, France, ⁷CHU Lille, Laboratoire d’Immunologie, F-59000 Lille, France, Lille, France
Background/Purpose: Antiphospholipid antibodies (aPL) have been found in patients with various autoimmune and rheumatic diseases, including systemic sclerosis (SSc). However, in the absence of clinical…
Abstract Number: 1062 • 2016 ACR/ARHP Annual Meeting
Non-Conventional Antiphospholipid Antibodies in Patients with Clinical Obstetrical APS: Prevalence and Pregnancies Treatment Efficacy
ARSENE MEKINIAN¹, Marie Charlotte Bourrienne², LIONEL CARBILLON³, AMELIE BENBARA⁴, SYLVIE CHOLLET MARTIN⁵, AHMED TIGAIZIN³, Francois Montestruc⁶, Olivier Fain⁷ and Pascale Nicaise-Roland⁸, ¹SAINT ANTOINE HOSPITAL, PARIS, France, ²Unité Fonctionnelles d'Immunologie « Autoimmunité et Hypersensibilités », AP-HP, Hôpital Bichat-Claude Bernard, Paris, paris, France, ³JEAN VERDIER HOSPITAL, BONDY, France, ⁴JEAN VERDIER HOSPITAL, PARIS, France, ⁵UNITE HYPERSENSIBILITE, PARIS, France, ⁶exystat, PARis, France, ⁷Internal Medicine Department, Saint Antoine Hospital, Paris, France, ⁸Immunology Department, Bichat Claude-bernard, Universitary Hospital, APHP, Paris, France
Background/Purpose: To describe the prevalence of non-conventional APL in patients with obstetrical APS pregnancy adverse outcome without conventional APL and the impact of treatment on…
Abstract Number: 2961 • 2016 ACR/ARHP Annual Meeting
Antiphospoholipid Antibodies in Adult IgA Vasculitis: Aps/PT Antibodies As a Potential Marker of Renal Involvement?
Alojzija Hocevar, Jaka Ostrovrsnik, Polona Žigon, Saša Čučnik, Ziga Rotar and Matija Tomšič, Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Increased prevalence of IgA aCL and anti-PS/PT antibodies has been described in adult IgAV, making them potential markers of disease activity1. The aim of our…
Abstract Number: 1066 • 2016 ACR/ARHP Annual Meeting
History of Lupus Nephritis Is an Independent Risk Factor for Thrombosis in Systemic Lupus Erythematosus Patients with Antiphospholipid Antibodies
Vinicius Domingues¹, Janet Nwaukoni², Jill P. Buyon³ and H. Michael Belmont⁴, ¹Rheumatology, NYU Langone Medical Center, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY
Background/Purpose: Few studies have analyzed the risk factors for thrombosis in Systemic Lupus Erythematosus (SLE) patients with antiphospholipid antibodies (aPL) and most had small sample…

« Previous Page
1
…
3
4
5
6
7
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].